// MedKitt â€” Drug Reference Store
// Centralized drug data for all medications used across decision trees.
// Each entry includes class, indications, dosing, contraindications, and citations.
// -------------------------------------------------------------------
// Drug Definitions (Alphabetical)
// -------------------------------------------------------------------
const ALTEPLASE = {
    id: 'alteplase',
    name: 'Alteplase (tPA)',
    genericName: 'Alteplase',
    drugClass: 'Thrombolytic (tissue plasminogen activator)',
    route: 'IV',
    indications: ['Massive (high-risk) pulmonary embolism', 'Acute ischemic stroke', 'Acute STEMI'],
    dosing: [
        {
            indication: 'High-risk PE',
            regimen: '100 mg IV over 2 hours: 0.6 mg/kg (max 50 mg) over first 15 min, remainder over next 1 hr 45 min. Stop UFH drip before infusion. Post-infusion: check PTT \u2014 if \u226475 restart UFH without bolus; if >75 repeat PTT q2hr until \u226475.',
        },
        {
            indication: 'Acute ischemic stroke (0\u20134.5h)',
            regimen: '0.9 mg/kg IV (max 90 mg): Give 10% as IV bolus over 1 min, remaining 90% infused over 60 min. BP must be <185/110 before and <180/105 for 24h after. No antithrombotics \u00D7 24h post-infusion.',
        },
    ],
    contraindications: [
        'Absolute: Haemorrhagic stroke or stroke of unknown origin, Ischaemic stroke within 6 months, CNS neoplasm, Major trauma/surgery/head injury within 3 weeks, Bleeding diathesis, Active bleeding',
        'Relative: TIA within 6 months, Oral anticoagulation, Pregnancy or first postpartum week, Non-compressible puncture sites, Traumatic resuscitation, Refractory HTN (SBP >180), Advanced liver disease, Infective endocarditis, Active peptic ulcer',
    ],
    monitoring: 'Assess hemodynamic response 1\u20132 hours post-infusion. Check PTT before restarting heparin.',
    notes: 'Fibrinolytic therapy is the first-line reperfusion strategy for high-risk PE with hemodynamic instability (ESC 2019, Class I, Level B).',
    citations: [
        'Konstantinides SV, et al. 2019 ESC Guidelines for Acute Pulmonary Embolism. Eur Heart J. 2020;41(4):543-603.',
    ],
};
const AMIODARONE = {
    id: 'amiodarone',
    name: 'Amiodarone',
    genericName: 'Amiodarone hydrochloride',
    drugClass: 'Class III antiarrhythmic (multichannel blocker)',
    route: 'IV / PO',
    indications: ['A-Fib / A-Flutter rate control', 'A-Fib / A-Flutter rhythm control (cardioversion)', 'Ventricular tachycardia', 'Cardiac arrest (VF/pulseless VT)'],
    dosing: [
        {
            indication: 'A-Fib rate control',
            regimen: 'Load: 150 mg IV over 10 min. Infusion: 1 mg/min x 6 hr, then 0.5 mg/min x 18 hr. May re-bolus 150 mg x2-3 PRN (total 150-450 mg boluses). Do not conclude failure without adequate re-bolusing.',
        },
        {
            indication: 'A-Fib rhythm control (cardioversion)',
            regimen: 'Load: 300 mg (or 5-7 mg/kg) IV over 30-60 min. Then 1 mg/min infusion. Total 24hr IV dose: 1,200-3,000 mg. Convert to PO 400 mg BID after >24hr IV, until 10g cumulative dose reached, then 200 mg daily maintenance.',
        },
        {
            indication: 'Cardiac arrest (VF/pVT)',
            regimen: '300 mg IV/IO push. May repeat 150 mg x1.',
        },
    ],
    contraindications: [
        'Cardiogenic shock',
        'Severe sinus node dysfunction without pacemaker',
        'Second/third-degree AV block without pacemaker',
        'Known hypersensitivity to iodine (contains iodine)',
    ],
    cautions: [
        'QT prolongation \u2014 monitor QTc, hold if QTc >500ms',
        'Hepatotoxicity \u2014 check LFTs at baseline and periodically',
        'Thyroid dysfunction (both hypo and hyper) \u2014 contains 37% iodine by weight',
        'Pulmonary toxicity with chronic use \u2014 baseline CXR and PFTs recommended',
        'Phlebitis with peripheral IV \u2014 use central line when possible for infusions >24hr',
        'Potentiates warfarin \u2014 reduce warfarin dose by 30-50% when initiating',
    ],
    monitoring: 'Continuous telemetry during IV loading. QTc interval. LFTs, TFTs, CXR at baseline. For chronic use: TFTs, LFTs, PFTs, ophthalmologic exam every 6-12 months.',
    notes: 'Amiodarone is useful for critically ill patients due to relative hemodynamic stability compared to beta-blockers and CCBs. Achieves rate control in ~74% of patients. Chemical cardioversion may occur \u2014 continue infusion until critical illness resolves to prevent AF recurrence. Chronic use causes numerous side effects \u2014 plan transition to safer long-term agent (e.g., beta-blocker) after recovery.',
    citations: [
        'Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS Guideline for AF. J Am Coll Cardiol. 2024;83(1):109-279.',
        'Wigginton JG, et al. 2025 AHA Guidelines: Adult Advanced Life Support. Circulation. 2025;152(16_suppl_2):S538-S577.',
        'Bosch NA, et al. Atrial Fibrillation in the ICU. Chest. 2018;154(6):1424-1434.',
    ],
};
const ASPIRIN = {
    id: 'aspirin',
    name: 'Aspirin',
    genericName: 'Acetylsalicylic acid',
    drugClass: 'Antiplatelet (COX inhibitor)',
    route: 'PO',
    indications: ['Acute ischemic stroke', 'Acute coronary syndrome', 'Secondary stroke prevention', 'DAPT (dual antiplatelet therapy)'],
    dosing: [
        {
            indication: 'Acute ischemic stroke (no IVT)',
            regimen: '160\u2013325 mg PO within 24\u201348 hours of symptom onset. If given via NG tube: use non-enteric-coated formulation or crush enteric-coated.',
        },
        {
            indication: 'Post-IVT stroke',
            regimen: 'Hold aspirin for 24 hours post-thrombolysis. Obtain NCCT at 24h to exclude hemorrhagic transformation before starting. Then 81\u2013325 mg daily.',
        },
        {
            indication: 'DAPT (minor stroke)',
            regimen: '325 mg loading dose + clopidogrel 300 mg on day 1. Then aspirin 81 mg + clopidogrel 75 mg daily \u00D7 21 days, followed by single antiplatelet.',
        },
    ],
    contraindications: [
        'Active intracranial hemorrhage',
        'Known aspirin allergy or NSAID-exacerbated respiratory disease',
        'Active GI bleeding',
    ],
    cautions: [
        'GI bleeding risk \u2014 consider PPI co-therapy if DAPT',
        'Platelet dysfunction lasts 7\u201310 days (irreversible COX inhibition)',
        'Avoid concurrent NSAIDs (competitive COX-1 binding reduces aspirin efficacy)',
    ],
    monitoring: 'No routine monitoring required. Monitor for signs of bleeding.',
    notes: 'Aspirin within 24\u201348h of acute ischemic stroke reduces early recurrent stroke (IST and CAST trials). DAPT with aspirin + clopidogrel for 21 days (POINT trial) reduces stroke recurrence in minor stroke/TIA (NNT 38) with modest bleeding increase.',
    citations: [
        'Powers WJ, et al. Guidelines for the Early Management of Acute Ischemic Stroke: 2019 Update. Stroke. 2019;50(12):e344-e418.',
        'Johnston SC, et al. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA (POINT). N Engl J Med. 2018;379(3):215-225.',
    ],
};
const APIXABAN = {
    id: 'apixaban',
    name: 'Apixaban',
    genericName: 'Apixaban',
    drugClass: 'Direct oral anticoagulant (Factor Xa inhibitor)',
    route: 'PO',
    indications: ['Pulmonary embolism', 'Deep vein thrombosis', 'Atrial fibrillation (stroke prevention)'],
    dosing: [
        {
            indication: 'PE / DVT treatment',
            regimen: '10 mg twice daily \u00D7 7 days, then 5 mg twice daily \u00D7 3\u20136 months. Extended therapy: 5 mg or 2.5 mg twice daily.',
        },
    ],
    cautions: [
        'Severe renal impairment (CrCl <25 mL/min) \u2014 limited data',
        'Moderate hepatic impairment (Child-Pugh B) \u2014 use with caution',
        'Strong CYP3A4 and P-gp inhibitors/inducers \u2014 avoid concomitant use',
    ],
    notes: 'Single-drug oral therapy \u2014 no initial parenteral heparin required. Particularly convenient for outpatient PE management.',
    citations: [
        'Kahn SR, de Wit K. Pulmonary Embolism. N Engl J Med. 2022.',
        'Renner E, Barnes GD. Antithrombotic Management of VTE: JACC Focus Seminar. J Am Coll Cardiol. 2020.',
    ],
};
const BIKTARVY = {
    id: 'biktarvy',
    name: 'Biktarvy (BIC/FTC/TAF)',
    genericName: 'Bictegravir / Emtricitabine / Tenofovir alafenamide',
    drugClass: 'INSTI + dual NRTI combination (single-tablet regimen)',
    route: 'PO',
    indications: ['HIV post-exposure prophylaxis (PEP)', 'HIV treatment (ART)'],
    dosing: [
        {
            indication: 'HIV PEP',
            regimen: '1 tablet (50/200/25 mg) PO once daily x 28 days. Take with or without food. Start as soon as possible, within 72 hours of exposure.',
        },
    ],
    contraindications: [
        'Co-administration with dofetilide',
        'Co-administration with rifampin (reduces bictegravir levels)',
    ],
    cautions: [
        'CrCl <30 mL/min \u2014 not recommended (limited data)',
        'Lactic acidosis / severe hepatomegaly with steatosis \u2014 rare but serious class effect of NRTIs',
        'HBV co-infection \u2014 severe hepatitis flare may occur upon discontinuation (contains FTC/TAF, active against HBV)',
        'Drug interactions \u2014 avoid polyvalent cation-containing antacids within 2 hours',
    ],
    monitoring: 'Renal function (BMP) at baseline and 2 weeks. HIV testing at baseline, 4\u20136 weeks, and 3 months.',
    notes: 'Preferred single-tablet PEP regimen per 2025 CDC guidelines. High barrier to resistance. Well tolerated with low discontinuation rates. TAF has less renal/bone toxicity than TDF.',
    citations: [
        'Tanner MR, et al. Antiretroviral PEP After Sexual, IDU, or Other Nonoccupational Exposure to HIV. MMWR. 2025;74(1):1-56.',
        'Gandhi RT, et al. Antiretroviral Drugs for Treatment and Prevention of HIV. JAMA. 2023;329(1):63-84.',
    ],
};
const BENZATHINE_PENICILLIN = {
    id: 'benzathine-penicillin',
    name: 'Benzathine Penicillin G',
    genericName: 'Benzathine penicillin G',
    drugClass: 'Natural penicillin (long-acting IM depot)',
    route: 'IM',
    indications: ['Primary syphilis', 'Secondary syphilis', 'Early latent syphilis', 'Late latent syphilis', 'Tertiary syphilis (non-neurologic)'],
    dosing: [
        {
            indication: 'Primary / Secondary / Early latent syphilis',
            regimen: '2.4 million units IM \u00D7 1 dose.',
        },
        {
            indication: 'Late latent / Tertiary syphilis (non-neurologic)',
            regimen: '2.4 million units IM weekly \u00D7 3 weeks (3 doses).',
        },
    ],
    contraindications: [
        'Penicillin allergy (IgE-mediated / anaphylaxis)',
    ],
    cautions: [
        'Jarisch-Herxheimer reaction \u2014 fever, myalgia, headache within 24 hr of treatment. Self-limited. More common in secondary syphilis.',
        'Does NOT achieve treponemicidal levels in CSF \u2014 not adequate for neurosyphilis.',
    ],
    monitoring: 'Quantitative RPR at 6, 12, and 24 months post-treatment. Expect 4-fold decline by 6\u201312 months.',
    citations: [
        'CDC. Sexually Transmitted Infections Treatment Guidelines. 2021.',
        'IDSA. Practice Guidelines for the Management of Syphilis. 2025.',
    ],
};
const CEFTRIAXONE = {
    id: 'ceftriaxone',
    name: 'Ceftriaxone',
    genericName: 'Ceftriaxone',
    drugClass: 'Third-generation cephalosporin',
    route: 'IV',
    indications: ['Neurosyphilis (PCN allergy alternative)', 'Bacterial meningitis', 'Various serious infections'],
    dosing: [
        {
            indication: 'Neurosyphilis (if desensitization not feasible)',
            regimen: '2 g IV daily \u00D7 10\u201314 days.',
        },
    ],
    contraindications: [
        'Severe cephalosporin allergy',
        'Note: ~2\u20135% cross-reactivity with penicillin allergy \u2014 lower than historically believed',
    ],
    cautions: [
        'Biliary sludging \u2014 avoid co-administration with calcium-containing IV solutions in neonates',
        'Not first-line for neurosyphilis \u2014 limited evidence compared to IV penicillin G. Use only if desensitization is not feasible.',
    ],
    monitoring: 'CSF re-examination at 6 months post-treatment to document improvement.',
    citations: [
        'CDC. Sexually Transmitted Infections Treatment Guidelines. 2021.',
        'Marra CM, et al. Ceftriaxone for Neurosyphilis. Clin Infect Dis. 2019.',
    ],
};
const DARUNAVIR = {
    id: 'darunavir',
    name: 'Darunavir (Prezista)',
    genericName: 'Darunavir',
    drugClass: 'Protease inhibitor (PI)',
    route: 'PO',
    indications: ['HIV post-exposure prophylaxis (alternative regimen)', 'HIV treatment (ART)'],
    dosing: [
        {
            indication: 'HIV PEP (alternative)',
            regimen: '800 mg PO once daily + ritonavir 100 mg PO once daily x 28 days. Must be taken with food. Always co-administer with ritonavir (pharmacokinetic booster).',
        },
    ],
    contraindications: [
        'Co-administration with alfuzosin, ergot derivatives, cisapride, pimozide, oral midazolam/triazolam, St. John\u2019s wort, lovastatin, simvastatin',
        'Severe hepatic impairment (Child-Pugh C)',
    ],
    cautions: [
        'Sulfonamide allergy \u2014 darunavir contains a sulfonamide moiety; use with caution',
        'Hepatotoxicity \u2014 monitor LFTs, especially in HBV/HCV co-infection',
        'Multiple CYP3A4 drug interactions \u2014 review full medication list',
        'Skin rash \u2014 including rare Stevens-Johnson syndrome',
    ],
    monitoring: 'LFTs at baseline and 2 weeks. Renal function. HIV testing at baseline, 4\u20136 weeks, and 3 months.',
    notes: 'Alternative 3rd agent for PEP when INSTI-based regimen cannot be used. Must be boosted with ritonavir. Higher pill burden and more drug interactions than dolutegravir.',
    citations: [
        'Tanner MR, et al. Antiretroviral PEP After Sexual, IDU, or Other Nonoccupational Exposure to HIV. MMWR. 2025;74(1):1-56.',
        'Gandhi RT, et al. Antiretroviral Drugs for Treatment and Prevention of HIV. JAMA. 2023;329(1):63-84.',
    ],
};
const CLEVIDIPINE = {
    id: 'clevidipine',
    name: 'Clevidipine (Cleviprex)',
    genericName: 'Clevidipine butyrate',
    drugClass: 'Ultra-short-acting dihydropyridine CCB',
    route: 'IV',
    indications: ['Acute hypertension in stroke (pre/post thrombolysis)', 'Perioperative hypertension', 'Hypertensive emergency'],
    dosing: [
        {
            indication: 'Acute stroke BP management',
            regimen: 'Start 1\u20132 mg/hr IV. Double dose every 90 seconds until target BP achieved. Usual maintenance: 4\u20136 mg/hr. Max 21 mg/hr (or 1000 mL per 24h due to lipid load).',
        },
    ],
    contraindications: [
        'Severe aortic stenosis',
        'Defective lipid metabolism (e.g., pathologic hyperlipidemia, lipoid nephrosis, acute pancreatitis with hyperlipidemia)',
        'Allergy to soy or egg products (lipid emulsion vehicle)',
    ],
    cautions: [
        'Lipid emulsion vehicle \u2014 contributes 2 kcal/mL to caloric intake',
        'No preservative \u2014 must be used within 12 hours of puncture',
        'Rebound hypertension possible if discontinued abruptly \u2014 transition to oral agent',
        'Reflex tachycardia may occur',
    ],
    monitoring: 'Continuous arterial BP monitoring recommended. Heart rate. Lipid panel if prolonged use >24h.',
    notes: 'Ultra-short half-life (~1 min) allows precise, rapid BP titration. Achieves target BP faster than nicardipine in clinical trials. Arterial-selective vasodilator \u2014 reduces afterload without venodilation. Does not reduce cerebral blood flow. Consider when nicardipine is unavailable or faster titration is needed.',
    citations: [
        'Powers WJ, et al. Guidelines for the Early Management of Acute Ischemic Stroke: 2019 Update. Stroke. 2019;50(12):e344-e418.',
        'Pollack CV, et al. Clevidipine for Acute Hypertension: A Systematic Review and Meta-Analysis. Crit Care Med. 2019.',
    ],
};
const CLOPIDOGREL = {
    id: 'clopidogrel',
    name: 'Clopidogrel (Plavix)',
    genericName: 'Clopidogrel bisulfate',
    drugClass: 'Antiplatelet (P2Y12 antagonist)',
    route: 'PO',
    indications: ['Minor ischemic stroke (DAPT)', 'High-risk TIA', 'Acute coronary syndrome', 'Secondary prevention (stent, PAD)'],
    dosing: [
        {
            indication: 'Minor stroke / high-risk TIA (DAPT)',
            regimen: '300 mg loading dose on day 1 + aspirin 325 mg. Then 75 mg daily + aspirin 81 mg \u00D7 21 days total DAPT. After 21 days: single antiplatelet (either agent).',
        },
    ],
    contraindications: [
        'Active pathological bleeding (intracranial hemorrhage, GI bleeding)',
        'Hypersensitivity to clopidogrel',
    ],
    cautions: [
        'CYP2C19 poor metabolizers \u2014 reduced conversion to active metabolite, diminished antiplatelet effect. Consider ticagrelor if known poor metabolizer.',
        'Concurrent omeprazole/esomeprazole \u2014 may reduce clopidogrel efficacy (CYP2C19 inhibition). Use pantoprazole if PPI needed.',
        'Hold 5\u20137 days before elective surgery',
        'Increased bleeding risk with DAPT \u2014 NNH 122 for moderate-severe hemorrhage (POINT trial)',
    ],
    monitoring: 'No routine monitoring. CYP2C19 genotyping if available may guide therapy. Monitor for bleeding.',
    notes: 'POINT trial: DAPT \u00D7 21 days reduced 90-day stroke from 6.5% to 5.0% (NNT 38) in minor stroke/TIA. CHANCE trial: similar benefit in Chinese population. Duration beyond 21 days increases bleeding without additional benefit.',
    citations: [
        'Johnston SC, et al. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA (POINT). N Engl J Med. 2018;379(3):215-225.',
        'Wang Y, et al. Clopidogrel with Aspirin in Acute Minor Stroke or TIA (CHANCE). N Engl J Med. 2013;369(1):11-19.',
    ],
};
const DABIGATRAN = {
    id: 'dabigatran',
    name: 'Dabigatran',
    genericName: 'Dabigatran etexilate',
    drugClass: 'Direct oral anticoagulant (Direct thrombin inhibitor)',
    route: 'PO',
    indications: ['Pulmonary embolism', 'Deep vein thrombosis', 'Atrial fibrillation (stroke prevention)'],
    dosing: [
        {
            indication: 'PE / DVT treatment',
            regimen: 'Requires 5\u201310 days parenteral anticoagulation (LMWH or UFH) first, then 150 mg twice daily.',
        },
    ],
    cautions: [
        'CrCl <30 mL/min \u2014 contraindicated (predominantly renal clearance ~80%)',
        'Strong P-gp inhibitors in CrCl <50 mL/min \u2014 dose reduction or avoidance',
        'No dose adjustment for hepatic impairment (not hepatically metabolized)',
    ],
    notes: 'Requires initial parenteral anticoagulation bridge (unlike apixaban/rivaroxaban). Specific reversal agent: idarucizumab (Praxbind).',
    citations: [
        'Kahn SR, de Wit K. Pulmonary Embolism. N Engl J Med. 2022.',
    ],
};
const DIGOXIN = {
    id: 'digoxin',
    name: 'Digoxin',
    genericName: 'Digoxin',
    drugClass: 'Cardiac glycoside',
    route: 'IV / PO',
    indications: ['A-Fib / A-Flutter rate control (adjunctive)', 'Heart failure with reduced EF'],
    dosing: [
        {
            indication: 'A-Fib rate control (acute)',
            regimen: 'IV loading: 0.25 mg IV every 2 hours, up to 1.5 mg total. Onset: ~3 hours (vs 5 min for diltiazem). Slow onset makes it unsuitable as sole agent for acute rate control.',
        },
        {
            indication: 'A-Fib rate control (maintenance)',
            regimen: '0.125-0.25 mg PO daily. Adjust for renal function and age.',
        },
    ],
    contraindications: [
        'Hypertrophic obstructive cardiomyopathy (HOCM)',
        'WPW syndrome with atrial fibrillation',
        'Ventricular tachycardia/fibrillation',
        'Severe hypokalemia (increases toxicity risk)',
    ],
    cautions: [
        'Renal impairment \u2014 reduce dose, monitor levels (CrCl <50: reduce dose 50%)',
        'Hypokalemia and hypomagnesemia potentiate toxicity',
        'Post hoc analyses associate digoxin with increased mortality in AF \u2014 use at low doses',
        'Limited exertional efficacy \u2014 slows primarily resting heart rate',
        'Narrow therapeutic index \u2014 toxicity at levels >2.0 ng/mL',
        'Drug interactions: amiodarone increases digoxin levels 70-100%',
    ],
    monitoring: 'Serum digoxin level (target 0.5-0.9 ng/mL for AF). Serum potassium, magnesium, creatinine. ECG for toxicity signs (ST scooping, PAT with block, bidirectional VT).',
    notes: 'Best used as adjunctive therapy when hypotension limits further titration of beta-blockers or CCBs. Particularly useful in patients with concurrent heart failure. Avoid as sole agent for acute rate control due to slow onset. Use at lowest effective dose given mortality concerns.',
    citations: [
        'Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS Guideline for AF. J Am Coll Cardiol. 2024;83(1):109-279.',
        'Michaud GF, Stevenson WG. Atrial Fibrillation. N Engl J Med. 2021;384(4):353-361.',
        'Ko D, et al. Atrial Fibrillation: A Review. JAMA. 2025;333(4):329-342.',
    ],
};
const DOLUTEGRAVIR = {
    id: 'dolutegravir',
    name: 'Dolutegravir (Tivicay)',
    genericName: 'Dolutegravir',
    drugClass: 'Integrase strand transfer inhibitor (INSTI)',
    route: 'PO',
    indications: ['HIV post-exposure prophylaxis (PEP)', 'HIV treatment (ART)'],
    dosing: [
        {
            indication: 'HIV PEP',
            regimen: '50 mg PO once daily x 28 days (with TDF/FTC backbone). Take with or without food.',
        },
    ],
    contraindications: [
        'Co-administration with dofetilide (increased dofetilide levels)',
    ],
    cautions: [
        'Drug interactions \u2014 avoid polyvalent cation-containing antacids/supplements within 2 hours (chelation reduces absorption)',
        'Metformin \u2014 dolutegravir increases metformin levels; limit metformin to 1000 mg/day',
        'Insomnia and neuropsychiatric effects \u2014 reported in some patients',
        'Weight gain \u2014 observed with long-term INSTI use',
    ],
    monitoring: 'HIV testing at baseline, 4\u20136 weeks, and 3 months. Renal function if on TDF backbone.',
    notes: 'Preferred 3rd agent for PEP when used with TDF/FTC backbone. High barrier to resistance. Well tolerated. Safe in pregnancy.',
    citations: [
        'Tanner MR, et al. Antiretroviral PEP After Sexual, IDU, or Other Nonoccupational Exposure to HIV. MMWR. 2025;74(1):1-56.',
        'Gandhi RT, et al. Antiretroviral Drugs for Treatment and Prevention of HIV. JAMA. 2023;329(1):63-84.',
    ],
};
const DILTIAZEM = {
    id: 'diltiazem',
    name: 'Diltiazem',
    genericName: 'Diltiazem hydrochloride',
    drugClass: 'Nondihydropyridine calcium channel blocker',
    route: 'IV',
    indications: ['A-Fib / A-Flutter rate control', 'Supraventricular tachycardia'],
    dosing: [
        {
            indication: 'A-Fib rate control (acute)',
            regimen: 'Initial bolus: 0.25 mg/kg IV over 2 min (typically 20-25 mg). If inadequate response after 15 min, second bolus: 0.35 mg/kg IV over 2 min. Then continuous infusion: 5-15 mg/hr, titrate to heart rate.',
        },
    ],
    contraindications: [
        'EF \u226440% or moderate-to-severe LV systolic dysfunction (Class 3: Harm)',
        'Decompensated heart failure',
        'Severe hypotension (SBP <90)',
        'Sick sinus syndrome without pacemaker',
        'Second/third-degree AV block without pacemaker',
        'WPW with atrial fibrillation',
        'Concurrent IV beta-blocker use',
    ],
    cautions: [
        'Hypotension \u2014 most common adverse effect, especially with continuous infusion',
        'Obtain echo or check history for EF if unknown \u2014 CCBs are dangerous in HFrEF',
        'Accumulation with prolonged infusions \u2014 monitor closely and titrate down when able',
        'Negative inotropic effects may worsen borderline hemodynamics',
        'Consider metoprolol over diltiazem in critically ill patients due to lower hypotension risk',
    ],
    monitoring: 'Continuous heart rate and blood pressure monitoring during IV infusion. Reassess hemodynamics frequently. Transition to oral rate control agent when stable.',
    notes: 'Achieves rate control more rapidly than digoxin or amiodarone (90% vs 74%, with faster time to HR <90). First-line for A-Fib rate control when EF >40%. Do NOT combine with IV beta-blockers \u2014 risk of synergistic hypotension and bradycardia.',
    citations: [
        'Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS Guideline for AF. J Am Coll Cardiol. 2024;83(1):109-279.',
        'Wigginton JG, et al. 2025 AHA Guidelines: Adult Advanced Life Support. Circulation. 2025;152(16_suppl_2):S538-S577.',
    ],
};
const DOXYCYCLINE = {
    id: 'doxycycline',
    name: 'Doxycycline',
    genericName: 'Doxycycline',
    drugClass: 'Tetracycline antibiotic',
    route: 'PO',
    indications: ['Syphilis (PCN allergy alternative)', 'Chlamydia', 'Tick-borne diseases', 'Acne', 'Malaria prophylaxis'],
    dosing: [
        {
            indication: 'Primary / Secondary / Early latent syphilis (PCN allergy)',
            regimen: '100 mg PO BID \u00D7 14 days.',
        },
        {
            indication: 'Late latent / Tertiary syphilis (PCN allergy)',
            regimen: '100 mg PO BID \u00D7 28 days.',
        },
    ],
    contraindications: [
        'Pregnancy \u2014 tetracyclines cause fetal bone/teeth abnormalities',
        'Children < 8 years (tooth discoloration)',
    ],
    cautions: [
        'Photosensitivity \u2014 advise sun protection',
        'Esophageal ulceration \u2014 take with full glass of water, remain upright 30 min',
        'Not adequate for neurosyphilis \u2014 poor CSF penetration',
    ],
    monitoring: 'Quantitative RPR at 6, 12, and 24 months post-treatment.',
    notes: 'Alternative for non-pregnant PCN-allergic patients with early syphilis. Evidence is weaker than for penicillin G.',
    citations: [
        'CDC. Sexually Transmitted Infections Treatment Guidelines. 2021.',
    ],
};
const EDOXABAN = {
    id: 'edoxaban',
    name: 'Edoxaban',
    genericName: 'Edoxaban',
    drugClass: 'Direct oral anticoagulant (Factor Xa inhibitor)',
    route: 'PO',
    indications: ['Pulmonary embolism', 'Deep vein thrombosis', 'Atrial fibrillation (stroke prevention)'],
    dosing: [
        {
            indication: 'PE / DVT treatment',
            regimen: 'Requires 5\u201310 days parenteral anticoagulation (LMWH) first, then 60 mg once daily. Reduce to 30 mg once daily if: CrCl 15\u201350 mL/min, body weight <60 kg, or concomitant P-glycoprotein inhibitors.',
        },
    ],
    cautions: [
        'CrCl >95 mL/min \u2014 reduced efficacy vs warfarin (avoid in AF indication)',
        'CrCl <15 mL/min \u2014 not recommended',
        'Moderate-severe hepatic impairment \u2014 not recommended',
    ],
    notes: 'Requires initial parenteral anticoagulation bridge. Once-daily dosing may improve adherence.',
    citations: [
        'Kahn SR, de Wit K. Pulmonary Embolism. N Engl J Med. 2022.',
    ],
};
const EPINEPHRINE = {
    id: 'epinephrine',
    name: 'Epinephrine (Intracavernosal)',
    genericName: 'Epinephrine',
    drugClass: 'Non-selective adrenergic agonist (alpha + beta)',
    route: 'Intracavernosal',
    indications: ['Ischemic priapism (alternative to phenylephrine)'],
    dosing: [
        {
            indication: 'Ischemic priapism',
            regimen: '20 mcg (2 mL of 10 mcg/mL solution) intracavernosal every 5 minutes, up to 5 doses total (100 mcg max). Mix: 1 mL epi from cardiac amp (100 mcg/mL) + 9 mL NS = 10 mcg/mL.',
        },
    ],
    contraindications: [
        'Uncontrolled hypertension',
        'MAO inhibitor use',
        'Do NOT give cardiac arrest doses (1 mg) to patients with a pulse',
    ],
    cautions: [
        'Has alpha AND beta1/2 effects \u2014 higher cardiovascular risk than phenylephrine',
        'Monitor BP and HR every 5 min between injections',
        'Hold if SBP > 160 or HR > 110',
    ],
    monitoring: 'BP/HR every 5 min during injections. Observe 60 min post-detumescence.',
    notes: 'Use only if phenylephrine is unavailable. Phenylephrine is preferred due to pure alpha-1 selectivity and lower cardiovascular risk. Onset: 1 min. Duration: 5\u201310 min.\n\nMIXING INSTRUCTIONS (10 mcg/mL):\n1. Take a 10 mL syringe and draw up 9 mL of normal saline\n2. Draw up 1 mL of epinephrine from the cardiac amp (cardiac amp contains 100 mcg/mL)\n3. Now you have 10 mL of epinephrine at 10 mcg/mL\n4. Each dose = 2 mL (20 mcg)\n\n\u26A0\uFE0F Do NOT give cardiac arrest doses (1 mg) to patients with a pulse.',
    citations: [
        'Bivalacqua TJ, et al. AUA/SMSNA Guideline on Priapism. J Urol. 2022;208(1):43-52.',
        'Graham BA, et al. Emergency Pharmacotherapy for Priapism. Expert Opin Pharmacother. 2022;23(12):1371-80.',
    ],
};
const ENOXAPARIN = {
    id: 'enoxaparin',
    name: 'Enoxaparin (LMWH)',
    genericName: 'Enoxaparin sodium',
    drugClass: 'Low molecular weight heparin',
    route: 'SC',
    indications: ['Pulmonary embolism', 'Deep vein thrombosis', 'ACS', 'VTE prophylaxis'],
    dosing: [
        {
            indication: 'PE / DVT treatment',
            regimen: '1 mg/kg SC every 12 hours, or 1.5 mg/kg SC once daily.',
        },
        {
            indication: 'VTE prophylaxis',
            regimen: '40 mg SC once daily.',
        },
    ],
    contraindications: [
        'Heparin-induced thrombocytopenia (HIT) \u2014 absolute contraindication due to cross-reactivity with HIT antibodies',
        'Active major bleeding',
    ],
    cautions: [
        'Severe renal insufficiency (CrCl \u226430 mL/min) \u2014 significantly increased bleeding risk (OR 2.25 for major bleeding). Consider UFH when CrCl <25\u201330 mL/min.',
        'Neuraxial anesthesia \u2014 administer LMWH \u226512 hr before catheter placement/removal; delay dosing \u22654 hr after removal. No twice-daily LMWH with indwelling neuraxial catheter.',
        'Extreme body weight (<40 kg or >100 kg), pregnancy, pediatrics \u2014 consider anti-Xa monitoring. Monitor if >150 kg.',
        'Effects cannot be completely reversed by protamine sulfate.',
    ],
    monitoring: 'Anti-Xa levels if renal impairment, extremes of weight, or pregnancy. Platelet count if > 4 days of therapy (HIT screening).',
    citations: [
        'Konstantinides SV, et al. 2019 ESC Guidelines for Acute Pulmonary Embolism. Eur Heart J. 2020.',
        'Garcia DA, et al. Parenteral Anticoagulants: ACCP Evidence-Based Clinical Practice Guidelines. Chest. 2012.',
    ],
};
const ESMOLOL = {
    id: 'esmolol',
    name: 'Esmolol',
    genericName: 'Esmolol hydrochloride',
    drugClass: 'Ultra-short-acting beta-1 selective blocker',
    route: 'IV',
    indications: ['A-Fib / A-Flutter rate control', 'Supraventricular tachycardia', 'Perioperative tachycardia/hypertension'],
    dosing: [
        {
            indication: 'A-Fib rate control',
            regimen: 'Loading dose: 500 mcg/kg IV over 1 minute. Infusion: 50-200 mcg/kg/min, titrate by 50 mcg/kg/min every 4 min. May repeat loading dose with each infusion increase.',
        },
    ],
    contraindications: [
        'Severe sinus bradycardia',
        'Heart block greater than first degree without pacemaker',
        'Cardiogenic shock',
        'Decompensated heart failure',
        'WPW with atrial fibrillation',
    ],
    cautions: [
        'Hypotension \u2014 may occur especially at higher infusion rates',
        'Must be given as continuous infusion \u2014 eliminated within 9 min of stopping',
        'Use cautiously in patients on calcium channel blockers \u2014 risk of additive bradycardia/hypotension',
        'Bronchospasm \u2014 theoretical risk, though beta-1 selectivity is lost at high doses',
    ],
    monitoring: 'Continuous heart rate and blood pressure monitoring during infusion. Effects resolve within minutes of discontinuation \u2014 ideal for titration.',
    notes: 'Ultra-short-acting beta-blocker (half-life ~9 min). Particularly useful when rapid titration or reversal is needed \u2014 if hypotension occurs, effects resolve within minutes of stopping infusion. Ideal for patients with uncertain hemodynamics or when testing beta-blocker tolerance before committing to longer-acting agents.',
    citations: [
        'Wigginton JG, et al. 2025 AHA Guidelines: Adult Advanced Life Support. Circulation. 2025;152(16_suppl_2):S538-S577.',
        'Prystowsky EN, et al. Treatment of Atrial Fibrillation. JAMA. 2015;314(3):278-88.',
    ],
};
const LIDOCAINE = {
    id: 'lidocaine',
    name: 'Lidocaine 1% (Without Epinephrine)',
    genericName: 'Lidocaine',
    drugClass: 'Amide local anesthetic',
    route: 'Local injection',
    indications: ['Dorsal penile nerve block', 'Local anesthesia for minor procedures', 'Nerve blocks'],
    dosing: [
        {
            indication: 'Dorsal penile nerve block',
            regimen: '10 mL total of 1% lidocaine WITHOUT epinephrine: 5 mL injected at 10 o\u2019clock and 5 mL at 2 o\u2019clock at penile base, under Buck\u2019s fascia.',
        },
    ],
    contraindications: [
        'Allergy to amide local anesthetics',
        'NEVER use with epinephrine on the penis \u2014 end-artery territory, risk of ischemic necrosis',
    ],
    cautions: [
        'Max dose without epi: 4.5 mg/kg',
        'Aspirate before injecting to avoid intravascular injection',
        'Wait 5\u201310 min for full anesthetic effect',
    ],
    monitoring: 'Test block adequacy with pinprick before procedure. Onset: 2\u20135 min. Duration: 30\u201360 min.',
    notes: 'For penile block, NEVER use formulations containing epinephrine. The penis is supplied by end-arteries \u2014 epinephrine can cause ischemic necrosis.',
    citations: [
        'Burnett AL, Sharlip ID. Standard Operating Procedures for Priapism. J Sex Med. 2013;10(1):180-94.',
    ],
};
const LABETALOL = {
    id: 'labetalol',
    name: 'Labetalol',
    genericName: 'Labetalol hydrochloride',
    drugClass: 'Combined alpha-1 and beta-adrenergic blocker',
    route: 'IV',
    indications: ['Acute stroke BP management (pre/post thrombolysis)', 'Hypertensive emergency', 'Preeclampsia/eclampsia'],
    dosing: [
        {
            indication: 'Pre-thrombolysis BP (target <185/110)',
            regimen: '10\u201320 mg IV bolus over 1\u20132 min. May repeat once. If BP still >185/110 after 2 doses, consider nicardipine infusion. Do NOT proceed with thrombolysis if BP remains uncontrolled.',
        },
        {
            indication: 'Post-thrombolysis BP (target <180/105 \u00D7 24h)',
            regimen: '10 mg IV bolus, then 2\u20138 mg/min continuous infusion. Titrate to maintain BP <180/105. Max 300 mg/24h.',
        },
    ],
    contraindications: [
        'Severe bradycardia (HR <60)',
        'Heart block greater than first degree without pacemaker',
        'Cardiogenic shock or decompensated HF',
        'Severe reactive airway disease / status asthmaticus',
        'Pheochromocytoma (without prior alpha-blockade)',
    ],
    cautions: [
        'Bronchospasm \u2014 beta-2 blockade at higher doses may precipitate bronchospasm in asthma/COPD',
        'Bradycardia \u2014 monitor HR; hold if HR <55',
        'Hepatotoxicity \u2014 rare idiosyncratic reaction; monitor LFTs if prolonged use',
        'Orthostatic hypotension \u2014 keep patient supine during IV administration',
    ],
    monitoring: 'Continuous BP monitoring (arterial line preferred). Heart rate. Neuro checks every 15 min during active titration.',
    notes: 'First-line IV antihypertensive for acute stroke per AHA/ASA guidelines. Onset: 2\u20135 min IV. Duration: 2\u20134 hours. Alpha:beta blockade ratio is ~1:7 (predominantly beta). Does not increase intracranial pressure. Preferred over nitroprusside (which can raise ICP).',
    citations: [
        'Powers WJ, et al. Guidelines for the Early Management of Acute Ischemic Stroke: 2019 Update. Stroke. 2019;50(12):e344-e418.',
        'Whelton PK, et al. 2017 ACC/AHA Guideline for Prevention, Detection, Evaluation, and Management of High Blood Pressure. J Am Coll Cardiol. 2018;71(19):e127-e248.',
    ],
};
const MAGNESIUM_SULFATE = {
    id: 'magnesium-sulfate',
    name: 'Magnesium Sulfate',
    genericName: 'Magnesium sulfate',
    drugClass: 'Electrolyte / Antiarrhythmic adjunct',
    route: 'IV',
    indications: ['A-Fib / A-Flutter adjunctive rate and rhythm control', 'Torsades de pointes', 'Hypomagnesemia', 'Eclampsia / Pre-eclampsia seizure prophylaxis'],
    dosing: [
        {
            indication: 'A-Fib (adjunctive)',
            regimen: 'Bolus: 2-4 g IV over 15-30 min. For aggressive repletion: continuous infusion per institutional protocol. Target serum level ~3-4 mg/dL for antiarrhythmic effect. Most administered magnesium is renally excreted \u2014 continuous infusion may be needed to replete intracellular stores.',
        },
        {
            indication: 'Torsades de pointes',
            regimen: '1-2 g IV over 5-60 min (faster for unstable patients).',
        },
    ],
    contraindications: [
        'Severe renal failure (GFR <30 mL/min or oliguria) for continuous infusion \u2014 use intermittent boluses instead',
        'Hypermagnesemia (>4 mg/dL)',
        'Myasthenia gravis (may worsen weakness)',
    ],
    cautions: [
        'Monitor for hypermagnesemia: loss of deep tendon reflexes (first sign), respiratory depression, cardiac arrest',
        'Check renal function before continuous infusion',
        'Calcium gluconate 1g IV is the antidote for magnesium toxicity',
    ],
    monitoring: 'Serum magnesium levels every 6-8 hours during infusion. Deep tendon reflexes. Respiratory rate. Renal function.',
    notes: 'Excellent safety profile \u2014 one meta-analysis detected no reported adverse events. Blocks slow calcium channels in SA and AV nodes. Even when cardioversion does not occur, magnesium reduces heart rate and augments efficacy of other antiarrhythmics and DC cardioversion. In one RCT, continuous magnesium infusion was superior to amiodarone for new-onset AF. The combination of aggressive magnesium loading plus amiodarone achieved 90% cardioversion rate in critically ill patients.',
    citations: [
        'Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS Guideline for AF. J Am Coll Cardiol. 2024;83(1):109-279.',
        'Moran JL, et al. Parenteral MgSO4 vs Amiodarone for Atrial Tachyarrhythmias. Crit Care Med. 1995;23(11):1816-24.',
        'Bosch NA, et al. Atrial Fibrillation in the ICU. Chest. 2018;154(6):1424-1434.',
    ],
};
const METOPROLOL = {
    id: 'metoprolol',
    name: 'Metoprolol',
    genericName: 'Metoprolol tartrate (IV) / Metoprolol succinate (PO)',
    drugClass: 'Beta-1 selective adrenergic blocker',
    route: 'IV / PO',
    indications: ['A-Fib / A-Flutter rate control', 'Hypertension', 'Heart failure (compensated, oral succinate)', 'Post-MI'],
    dosing: [
        {
            indication: 'A-Fib rate control (acute)',
            regimen: 'IV: 2.5-5 mg IV push over 2 min. Repeat every 5 min as needed, up to 15 mg total (3 doses).',
        },
        {
            indication: 'A-Fib rate control (maintenance)',
            regimen: 'PO tartrate: 25-100 mg BID. PO succinate (Toprol XL): 25-200 mg daily.',
        },
    ],
    contraindications: [
        'Severe sinus bradycardia (HR <50)',
        'Heart block greater than first degree without pacemaker',
        'Cardiogenic shock',
        'Decompensated heart failure (acute)',
        'WPW with atrial fibrillation',
    ],
    cautions: [
        'Safe in COPD \u2014 multiple studies demonstrate no adverse respiratory effects',
        'Use cautiously in decompensated HF but safe in compensated HFrEF',
        'May mask hypoglycemia symptoms in diabetic patients',
        'Do NOT combine with IV calcium channel blockers',
        'Intermittent dosing naturally encourages dose-by-dose reassessment \u2014 advantage over continuous infusions in unstable patients',
    ],
    monitoring: 'Heart rate and blood pressure before each IV dose. Hold if SBP <90 or HR <55.',
    notes: 'First-line for A-Fib rate control (Class 1 recommendation). Preferred in patients with CAD or compensated HFrEF. Many critically ill patients develop AF due to increased sympathetic tone \u2014 beta-blockers address the underlying physiological problem. A retrospective ICU study found lower failure rates with metoprolol vs diltiazem.',
    citations: [
        'Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS Guideline for AF. J Am Coll Cardiol. 2024;83(1):109-279.',
        'Wigginton JG, et al. 2025 AHA Guidelines: Adult Advanced Life Support. Circulation. 2025;152(16_suppl_2):S538-S577.',
        'Moskowitz A, et al. Management of AF with RVR in the ICU. Shock. 2017;48(4):436-440.',
    ],
};
const NICARDIPINE = {
    id: 'nicardipine',
    name: 'Nicardipine (Cardene)',
    genericName: 'Nicardipine hydrochloride',
    drugClass: 'Dihydropyridine calcium channel blocker',
    route: 'IV',
    indications: ['Acute stroke BP management (pre/post thrombolysis)', 'Hypertensive emergency', 'Perioperative hypertension'],
    dosing: [
        {
            indication: 'Pre-thrombolysis BP (target <185/110)',
            regimen: '5 mg/hr IV infusion. Titrate by 2.5 mg/hr every 5\u201315 min. Max 15 mg/hr. Once target achieved, decrease to 3 mg/hr and titrate to maintain.',
        },
        {
            indication: 'Post-thrombolysis BP (target <180/105 \u00D7 24h)',
            regimen: '5 mg/hr IV infusion, titrate by 2.5 mg/hr every 5\u201315 min to maintain BP <180/105. Max 15 mg/hr.',
        },
    ],
    contraindications: [
        'Advanced aortic stenosis',
        'Hypersensitivity to nicardipine or other dihydropyridine CCBs',
    ],
    cautions: [
        'Reflex tachycardia \u2014 may need to combine with beta-blocker',
        'Peripheral phlebitis \u2014 change IV site every 12h or use central line',
        'Hepatic impairment \u2014 reduce dose (extensively hepatically metabolized)',
        'Transition to oral antihypertensive when stable \u2014 onset of oral agent overlaps with nicardipine wean',
    ],
    monitoring: 'Continuous arterial BP monitoring recommended. Heart rate. IV site inspection every 4\u20136h (phlebitis risk).',
    notes: 'Second-line to labetalol for acute stroke BP management. Preferred when beta-blocker contraindicated (asthma, bradycardia, HF). Onset: 5\u201310 min. Does not increase ICP. Arterial-selective vasodilator. More predictable dose-response than labetalol for continuous infusion.',
    citations: [
        'Powers WJ, et al. Guidelines for the Early Management of Acute Ischemic Stroke: 2019 Update. Stroke. 2019;50(12):e344-e418.',
        'Liu-Deryke X, et al. Management of Hypertension in Acute Ischemic Stroke. Ann Pharmacother. 2006;40(12):2234-46.',
    ],
};
const PENICILLIN_G_IV = {
    id: 'penicillin-g-iv',
    name: 'Penicillin G (Aqueous Crystalline)',
    genericName: 'Aqueous crystalline penicillin G',
    drugClass: 'Natural penicillin (IV formulation)',
    route: 'IV',
    indications: ['Neurosyphilis', 'Ocular syphilis', 'Otosyphilis'],
    dosing: [
        {
            indication: 'Neurosyphilis / Ocular / Otic syphilis',
            regimen: '18\u201324 million units/day IV, given as 3\u20134 million units IV q4h \u00D7 10\u201314 days. Achieves treponemicidal levels in CSF.',
        },
    ],
    contraindications: [
        'Penicillin allergy (IgE-mediated / anaphylaxis) \u2014 consider desensitization if no alternative',
    ],
    cautions: [
        'Jarisch-Herxheimer reaction \u2014 more common with higher organism burden',
        'Requires IV access and inpatient admission for duration of therapy',
    ],
    monitoring: 'CSF re-examination at 6 months. If CSF cell count not normalized, consider re-treatment. Quantitative RPR at 6, 12, 24 months.',
    citations: [
        'CDC. Sexually Transmitted Infections Treatment Guidelines. 2021.',
        'Ropper AH. Neurosyphilis. N Engl J Med. 2019;381(14):1358-1363.',
    ],
};
const PROCAINAMIDE = {
    id: 'procainamide',
    name: 'Procainamide',
    genericName: 'Procainamide hydrochloride',
    drugClass: 'Class IA antiarrhythmic (sodium channel blocker)',
    route: 'IV',
    indications: ['WPW with atrial fibrillation', 'Wide-complex tachycardia of uncertain origin', 'Atrial fibrillation (pharmacologic cardioversion \u2014 second-tier)'],
    dosing: [
        {
            indication: 'WPW + A-Fib / Wide-complex tachycardia',
            regimen: 'Loading: 20-50 mg/min IV infusion until arrhythmia suppressed, hypotension occurs, QRS widens >50%, or max dose 17 mg/kg reached. Maintenance: 1-4 mg/min IV infusion.',
        },
    ],
    contraindications: [
        'QT prolongation (QTc >500 ms)',
        'Torsades de pointes',
        'Complete heart block without pacemaker',
        'Systemic lupus erythematosus (drug may exacerbate)',
    ],
    cautions: [
        'Hypotension with rapid infusion \u2014 administer slowly',
        'QRS and QT prolongation \u2014 stop if QRS widens >50% from baseline',
        'Drug-induced lupus with chronic use',
        'Reduce dose in renal impairment (active metabolite NAPA is renally cleared)',
        'Monitor QTc continuously during loading',
    ],
    monitoring: 'Continuous ECG monitoring during loading. Blood pressure every 5 min. QRS width and QT interval. NAPA levels if chronic use.',
    notes: 'Key role in WPW + A-Fib where AV nodal blockers (beta-blockers, CCBs, digoxin, IV amiodarone) are contraindicated. Slows conduction through the accessory pathway. Also useful for wide-complex tachycardia of uncertain origin. Second-tier recommendation for pharmacologic cardioversion of AF per 2025 AHA guidelines.',
    citations: [
        'Wigginton JG, et al. 2025 AHA Guidelines: Adult Advanced Life Support. Circulation. 2025;152(16_suppl_2):S538-S577.',
        'Panchal AR, et al. 2020 AHA Guidelines: Adult BLS and ALS. Circulation. 2020;142(16_suppl_2):S366-S468.',
    ],
};
const PROCAINE_PENICILLIN = {
    id: 'procaine-penicillin',
    name: 'Procaine Penicillin G + Probenecid',
    genericName: 'Procaine penicillin G with probenecid',
    drugClass: 'Natural penicillin (IM depot) + renal tubular secretion inhibitor',
    route: 'IM + PO',
    indications: ['Neurosyphilis (alternative to IV penicillin G)'],
    dosing: [
        {
            indication: 'Neurosyphilis',
            regimen: 'Procaine penicillin G 2.4 million units IM daily + probenecid 500 mg PO QID, both \u00D7 10\u201314 days.',
        },
    ],
    contraindications: [
        'Penicillin allergy',
        'Procaine allergy (rare)',
    ],
    cautions: [
        'Probenecid: avoid in renal stones, acute gout flare',
        'Requires daily IM injections \u2014 patient tolerance/compliance',
    ],
    notes: 'Equivalent outcomes to IV penicillin G for neurosyphilis (Dunaway et al., CID 2020). Allows outpatient treatment.',
    citations: [
        'CDC. Sexually Transmitted Infections Treatment Guidelines. 2021.',
        'Dunaway SB, et al. Procaine Penicillin G vs Aqueous Crystalline Penicillin G for Neurosyphilis. Clin Infect Dis. 2020.',
    ],
};
const PHENYLEPHRINE = {
    id: 'phenylephrine',
    name: 'Phenylephrine (Intracavernosal)',
    genericName: 'Phenylephrine',
    drugClass: 'Selective alpha-1 adrenergic agonist',
    route: 'Intracavernosal',
    indications: ['Ischemic priapism (first-line)', 'Post-ICI prolonged erection'],
    dosing: [
        {
            indication: 'Ischemic priapism',
            regimen: '200 mcg (2 mL of 100 mcg/mL solution) intracavernosal every 5 minutes, up to 5 doses total (1 mg max). Corpora cavernosa communicate freely \u2014 inject one side only. Mix: 1 mL phenylephrine from vial (10 mg/mL) into 100 mL NS = 100 mcg/mL.',
        },
        {
            indication: 'Pediatric / Sickle cell',
            regimen: '100 mcg (1 mL of 100 mcg/mL) per injection. Lower dose recommended.',
        },
    ],
    contraindications: [
        'Uncontrolled hypertension',
        'MAO inhibitor use',
    ],
    cautions: [
        'Monitor BP and HR every 5 min between injections',
        'Hold if SBP > 160 or HR > 110',
        'Pure alpha-1 agonist \u2014 no intrinsic inotropy, no heart rate increase',
    ],
    monitoring: 'BP/HR every 5 min during injections. Observe 60 min post-detumescence.',
    notes: 'First-line sympathomimetic for ischemic priapism (AUA/SMSNA 2022). Alpha-1 selective = lower cardiovascular risk than epinephrine. 74% success alone, 70\u2013100% combined with aspiration. Onset: 1 min. Duration: 10\u201320 min.\n\nMIXING INSTRUCTIONS (100 mcg/mL):\n1. Take a 3 mL syringe, draw up 1 mL of phenylephrine from the vial (vial contains 10 mg/mL)\n2. Inject this 1 mL into a 100 mL bag of normal saline\n3. Now you have 100 mL of phenylephrine at 100 mcg/mL\n4. Draw up into a syringe \u2014 each 1 mL = 100 mcg\n5. Each dose = 2 mL (200 mcg)',
    image: {
        src: 'images/priapism/mixing-instructions.png',
        alt: 'Mixing instructions for phenylephrine (100 mcg/mL) showing vials, syringes, and labeled concentrations',
        caption: 'Mixing instructions for intracavernosal phenylephrine. (Source: EMCrit Podcast / EM:RAP)',
    },
    citations: [
        'Bivalacqua TJ, et al. AUA/SMSNA Guideline on Priapism. J Urol. 2022;208(1):43-52.',
        'Martin C, Cocchio C. Phenylephrine vs Terbutaline for Ischemic Priapism. Am J Emerg Med. 2016;34(2):222-4.',
        'Graham BA, et al. Emergency Pharmacotherapy for Priapism. Expert Opin Pharmacother. 2022;23(12):1371-80.',
    ],
};
const RITONAVIR = {
    id: 'ritonavir',
    name: 'Ritonavir (Norvir)',
    genericName: 'Ritonavir',
    drugClass: 'Protease inhibitor (pharmacokinetic booster)',
    route: 'PO',
    indications: ['Pharmacokinetic booster for darunavir (PEP alternative)', 'Pharmacokinetic booster for other PIs'],
    dosing: [
        {
            indication: 'PK booster for darunavir (PEP)',
            regimen: '100 mg PO once daily x 28 days. Always co-administer with darunavir 800 mg. Take with food.',
        },
    ],
    contraindications: [
        'Co-administration with alfuzosin, amiodarone, flecainide, ergot derivatives, lovastatin, simvastatin, pimozide, sildenafil (for PAH), oral midazolam/triazolam',
    ],
    cautions: [
        'Potent CYP3A4 inhibitor \u2014 extensive drug interactions; review full medication list',
        'GI side effects (nausea, diarrhea, dysgeusia) \u2014 common at boosting doses',
        'Hepatotoxicity \u2014 monitor LFTs in hepatic impairment',
        'Lipid elevations with prolonged use',
    ],
    monitoring: 'LFTs at baseline. Review drug interaction list before prescribing.',
    notes: 'Used at sub-therapeutic dose (100 mg) solely as a pharmacokinetic booster to increase darunavir levels via CYP3A4 inhibition. Not used as a standalone antiretroviral at this dose.',
    citations: [
        'Gandhi RT, et al. Antiretroviral Drugs for Treatment and Prevention of HIV. JAMA. 2023;329(1):63-84.',
    ],
};
const RIVAROXABAN = {
    id: 'rivaroxaban',
    name: 'Rivaroxaban',
    genericName: 'Rivaroxaban',
    drugClass: 'Direct oral anticoagulant (Factor Xa inhibitor)',
    route: 'PO',
    indications: ['Pulmonary embolism', 'Deep vein thrombosis', 'Atrial fibrillation (stroke prevention)', 'CAD/PAD secondary prevention'],
    dosing: [
        {
            indication: 'PE / DVT treatment',
            regimen: '15 mg twice daily with food \u00D7 21 days, then 20 mg once daily with food \u00D7 3\u20136 months. Extended therapy: 20 mg or 10 mg once daily.',
        },
    ],
    cautions: [
        'CrCl <30 mL/min \u2014 avoid (limited data, increased drug exposure)',
        'Moderate hepatic impairment (Child-Pugh B) \u2014 use with caution',
        'Must take with food (increases bioavailability by 39%)',
        'Strong CYP3A4 and P-gp inhibitors/inducers \u2014 avoid concomitant use',
    ],
    notes: 'Single-drug oral therapy \u2014 no initial parenteral heparin required. Take with food to ensure adequate absorption.',
    citations: [
        'Kahn SR, de Wit K. Pulmonary Embolism. N Engl J Med. 2022.',
        'Freund Y, et al. Acute Pulmonary Embolism: A Review. JAMA. 2022.',
    ],
};
const TDF_FTC = {
    id: 'tdf-ftc',
    name: 'Tenofovir/Emtricitabine (Truvada)',
    genericName: 'Tenofovir disoproxil fumarate / Emtricitabine',
    drugClass: 'Dual NRTI combination (backbone)',
    route: 'PO',
    indications: ['HIV post-exposure prophylaxis (PEP backbone)', 'HIV pre-exposure prophylaxis (PrEP)', 'HIV treatment (ART backbone)'],
    dosing: [
        {
            indication: 'HIV PEP (backbone)',
            regimen: '1 tablet (300/200 mg) PO once daily x 28 days. Combine with dolutegravir 50 mg daily or darunavir/ritonavir. Take with or without food.',
        },
    ],
    contraindications: [
        'CrCl <60 mL/min for TDF-based formulations (nephrotoxic)',
    ],
    cautions: [
        'Renal toxicity (TDF) \u2014 monitor creatinine at baseline and 2 weeks; avoid if CrCl <60',
        'Bone mineral density decrease \u2014 TDF associated with bone loss (TAF-based alternatives preferred if risk factors)',
        'Lactic acidosis / hepatomegaly with steatosis \u2014 rare NRTI class effect',
        'HBV co-infection \u2014 severe hepatitis flare may occur upon discontinuation (both FTC and TDF active against HBV)',
    ],
    monitoring: 'Renal function at baseline and 2 weeks. HIV testing at baseline, 4\u20136 weeks, and 3 months. HBV serology at baseline.',
    notes: 'Preferred dual-NRTI backbone for PEP when used with a 3rd agent (dolutegravir or darunavir/r). Also used for PrEP. TAF-based alternatives (e.g., Biktarvy, Descovy) have less renal/bone toxicity.',
    citations: [
        'Tanner MR, et al. Antiretroviral PEP After Sexual, IDU, or Other Nonoccupational Exposure to HIV. MMWR. 2025;74(1):1-56.',
        'Gandhi RT, et al. Antiretroviral Drugs for Treatment and Prevention of HIV. JAMA. 2023;329(1):63-84.',
    ],
};
const TENECTEPLASE = {
    id: 'tenecteplase',
    name: 'Tenecteplase (TNKase)',
    genericName: 'Tenecteplase',
    drugClass: 'Thrombolytic (tissue plasminogen activator)',
    route: 'IV',
    indications: ['Acute ischemic stroke (0\u20134.5h)', 'Acute STEMI'],
    dosing: [
        {
            indication: 'Acute ischemic stroke',
            regimen: '0.25 mg/kg IV bolus (max 25 mg) given over 5 seconds. Single dose \u2014 no infusion required. BP must be <185/110 before administration and <180/105 for 24h after.',
        },
    ],
    contraindications: [
        'Active internal bleeding or ICH',
        'History of hemorrhagic stroke or stroke of unknown origin',
        'Ischemic stroke within 3 months',
        'Intracranial neoplasm, AVM, or aneurysm',
        'Known bleeding diathesis',
        'Severe uncontrolled hypertension (>185/110 despite treatment)',
        'See full contraindications list in [Thrombolysis Contraindications](#/info/stroke-contraindications)',
    ],
    cautions: [
        'No antithrombotics \u00D7 24h post-administration',
        'Repeat NCCT at 24h before starting antiplatelets/anticoagulants',
        'Angioedema risk \u2014 higher in patients on ACE inhibitors',
        'Fibrinogen depletion less than alteplase (more fibrin-specific)',
    ],
    monitoring: 'Neuro checks every 15 min \u00D7 2h, then every 30 min \u00D7 6h, then hourly \u00D7 16h. BP every 15 min \u00D7 2h, then every 30 min \u00D7 6h. Any neurological decline \u2192 emergent NCCT.',
    notes: 'Single IV bolus (vs 60-min alteplase infusion) \u2014 significantly simpler administration. AcT trial (2024): tenecteplase 0.25 mg/kg was noninferior to alteplase for functional outcome at 90 days with similar safety profile. Preferred thrombolytic per 2026 AHA/ASA guidelines due to ease of administration and equivalent efficacy.',
    citations: [
        'Mendelson SJ, Prabhakaran S. Diagnosis and Management of Transient Ischemic Attack and Acute Ischemic Stroke: A Review. JAMA. 2021;325(11):1088-1098.',
        'Bhatt DL, et al. Tenecteplase vs Alteplase for Acute Ischemic Stroke (AcT). Lancet. 2024.',
        'Powers WJ, et al. Guidelines for the Early Management of Acute Ischemic Stroke: 2019 Update. Stroke. 2019;50(12):e344-e418.',
    ],
};
const TICAGRELOR = {
    id: 'ticagrelor',
    name: 'Ticagrelor (Brilinta)',
    genericName: 'Ticagrelor',
    drugClass: 'Antiplatelet (reversible P2Y12 antagonist)',
    route: 'PO',
    indications: ['Minor ischemic stroke (alternative DAPT)', 'High-risk TIA', 'Acute coronary syndrome'],
    dosing: [
        {
            indication: 'Minor stroke / high-risk TIA (alternative DAPT)',
            regimen: '180 mg loading dose on day 1 + aspirin 325 mg. Then 90 mg BID + aspirin 81 mg \u00D7 30 days total. Alternative to aspirin + clopidogrel when CYP2C19 poor metabolizer status is known or suspected.',
        },
    ],
    contraindications: [
        'Active pathological bleeding',
        'History of intracranial hemorrhage',
        'Severe hepatic impairment (Child-Pugh C)',
    ],
    cautions: [
        'Dyspnea \u2014 occurs in ~14% of patients; usually mild, self-limited, not related to bronchospasm',
        'Bradycardia \u2014 ventricular pauses reported; use cautiously with sick sinus syndrome or AV block',
        'Do not exceed aspirin 100 mg/day with ticagrelor (higher aspirin doses reduce ticagrelor efficacy)',
        'Reversible antiplatelet effect \u2014 offset ~5 days (vs 7\u201310 days for clopidogrel)',
        'CYP3A4 interactions \u2014 avoid strong inhibitors (ketoconazole) and strong inducers (rifampin)',
    ],
    monitoring: 'No routine monitoring required. Monitor for bleeding and dyspnea.',
    notes: 'THALES trial: ticagrelor + aspirin \u00D7 30 days reduced 30-day stroke/death from 6.6% to 5.5% (NNT 91) in mild-to-moderate stroke. Not dependent on CYP2C19 metabolism (advantage over clopidogrel in poor metabolizers). Higher cost and twice-daily dosing compared to clopidogrel.',
    citations: [
        'Johnston SC, et al. Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA (THALES). N Engl J Med. 2020;383(3):207-217.',
    ],
};
const UFH = {
    id: 'ufh',
    name: 'Unfractionated Heparin (UFH)',
    genericName: 'Heparin sodium',
    drugClass: 'Unfractionated heparin (indirect thrombin/Xa inhibitor)',
    route: 'IV',
    indications: ['Pulmonary embolism (all risk levels)', 'DVT', 'ACS', 'Bridge anticoagulation'],
    dosing: [
        {
            indication: 'High-risk / Massive PE',
            regimen: 'Bolus 80 units/kg (or 5,000 units) IV, then continuous infusion at 18 units/kg/hour. Titrate to aPTT 60\u201380 seconds (1.5\u20132.5\u00D7 control).',
        },
        {
            indication: 'Standard PE / DVT',
            regimen: 'Bolus 80 units/kg IV, then 18 units/kg/hr continuous infusion. Adjust per institutional nomogram.',
        },
    ],
    contraindications: [
        'Active major hemorrhage',
        'Severe thrombocytopenia (platelets <25,000)',
        'History of heparin-induced thrombocytopenia (HIT)',
        'Spinal procedure or epidural within 12 hours',
    ],
    cautions: [
        'Renal insufficiency: UFH preferred over LMWH when CrCl <25\u201330 mL/min (not renally cleared)',
        'Obesity: may require higher initial doses and more frequent aPTT monitoring',
    ],
    monitoring: 'aPTT every 6 hours until therapeutic, then every 12\u201324 hours. Platelet count at baseline and every 2\u20133 days (HIT screening).',
    notes: 'Preferred over LMWH when: CrCl <30 mL/min, high bleeding risk (short half-life, fully reversible with protamine), or thrombolysis anticipated. Fully reversible with protamine sulfate.',
    citations: [
        'Konstantinides SV, et al. 2019 ESC Guidelines for Acute Pulmonary Embolism. Eur Heart J. 2020.',
        'Garcia DA, et al. Parenteral Anticoagulants: ACCP Evidence-Based Clinical Practice Guidelines. Chest. 2012.',
    ],
};
const VERAPAMIL = {
    id: 'verapamil',
    name: 'Verapamil',
    genericName: 'Verapamil hydrochloride',
    drugClass: 'Nondihydropyridine calcium channel blocker',
    route: 'IV',
    indications: ['A-Fib / A-Flutter rate control', 'Supraventricular tachycardia'],
    dosing: [
        {
            indication: 'A-Fib rate control (acute)',
            regimen: '2.5-5 mg IV over 2 min. May repeat with 5-10 mg every 15-30 min as needed. Maximum total dose: 20 mg.',
        },
    ],
    contraindications: [
        'EF \u226440% or moderate-to-severe LV systolic dysfunction',
        'Decompensated heart failure',
        'Severe hypotension',
        'Sick sinus syndrome without pacemaker',
        'Second/third-degree AV block without pacemaker',
        'WPW with atrial fibrillation',
        'Concurrent IV beta-blocker use',
        'Wide-complex tachycardia of uncertain origin',
    ],
    cautions: [
        'Hypotension \u2014 more common than with diltiazem',
        'Negative inotropic effects \u2014 may worsen borderline hemodynamics',
        'Randomized clinical trials examining verapamil for A-Fib are lacking',
        'Diltiazem is generally preferred among nondihydropyridine CCBs',
    ],
    monitoring: 'Continuous heart rate and blood pressure monitoring. Assess hemodynamic response after each dose.',
    notes: 'Alternative to diltiazem when diltiazem is unavailable. Generally less preferred due to limited RCT evidence and similar contraindication profile. Same EF restriction as diltiazem: CONTRAINDICATED if EF \u226440%.',
    citations: [
        'Wigginton JG, et al. 2025 AHA Guidelines: Adult Advanced Life Support. Circulation. 2025;152(16_suppl_2):S538-S577.',
        'Prystowsky EN, et al. Treatment of Atrial Fibrillation. JAMA. 2015;314(3):278-88.',
    ],
};
// -------------------------------------------------------------------
// Drug Registry (Alphabetical by name)
// -------------------------------------------------------------------
export const ALL_DRUGS = [
    ALTEPLASE,
    AMIODARONE,
    APIXABAN,
    ASPIRIN,
    BENZATHINE_PENICILLIN,
    BIKTARVY,
    CEFTRIAXONE,
    CLEVIDIPINE,
    CLOPIDOGREL,
    DABIGATRAN,
    DARUNAVIR,
    DIGOXIN,
    DILTIAZEM,
    DOLUTEGRAVIR,
    DOXYCYCLINE,
    EDOXABAN,
    ENOXAPARIN,
    EPINEPHRINE,
    ESMOLOL,
    LABETALOL,
    LIDOCAINE,
    MAGNESIUM_SULFATE,
    METOPROLOL,
    NICARDIPINE,
    PENICILLIN_G_IV,
    PHENYLEPHRINE,
    PROCAINAMIDE,
    PROCAINE_PENICILLIN,
    RITONAVIR,
    RIVAROXABAN,
    TDF_FTC,
    TENECTEPLASE,
    TICAGRELOR,
    UFH,
    VERAPAMIL,
];
const DRUG_MAP = {};
for (const drug of ALL_DRUGS) {
    DRUG_MAP[drug.id] = drug;
}
/** Get a drug by ID */
export function getDrug(id) {
    return DRUG_MAP[id];
}
/** Get all drugs (already sorted alphabetically) */
export function getAllDrugs() {
    return ALL_DRUGS;
}
/** Lookup table: maps common drug name fragments to drug store IDs */
const NAME_TO_ID = [
    [/alteplase|tPA/i, 'alteplase'],
    [/amiodarone|cordarone/i, 'amiodarone'],
    [/apixaban/i, 'apixaban'],
    [/aspirin|ASA|acetylsalicylic/i, 'aspirin'],
    [/biktarvy|BIC\/FTC\/TAF/i, 'biktarvy'],
    [/benzathine.*penicillin/i, 'benzathine-penicillin'],
    [/ceftriaxone/i, 'ceftriaxone'],
    [/clevidipine|cleviprex/i, 'clevidipine'],
    [/clopidogrel|plavix/i, 'clopidogrel'],
    [/dabigatran/i, 'dabigatran'],
    [/darunavir|prezista/i, 'darunavir'],
    [/digoxin|digitalis|lanoxin/i, 'digoxin'],
    [/diltiazem|cardizem/i, 'diltiazem'],
    [/dolutegravir|tivicay/i, 'dolutegravir'],
    [/doxycycline/i, 'doxycycline'],
    [/edoxaban/i, 'edoxaban'],
    [/enoxaparin|LMWH|low.molecular/i, 'enoxaparin'],
    [/epinephrine|adrenaline/i, 'epinephrine'],
    [/esmolol|brevibloc/i, 'esmolol'],
    [/labetalol/i, 'labetalol'],
    [/lidocaine/i, 'lidocaine'],
    [/magnesium sulfate|mag sulfate|MgSO4/i, 'magnesium-sulfate'],
    [/metoprolol|lopressor|toprol/i, 'metoprolol'],
    [/nicardipine|cardene/i, 'nicardipine'],
    [/aqueous.*penicillin|penicillin G.*IV|crystalline.*penicillin/i, 'penicillin-g-iv'],
    [/phenylephrine/i, 'phenylephrine'],
    [/procainamide|pronestyl/i, 'procainamide'],
    [/procaine.*penicillin/i, 'procaine-penicillin'],
    [/ritonavir|norvir/i, 'ritonavir'],
    [/rivaroxaban/i, 'rivaroxaban'],
    [/tenecteplase|TNKase/i, 'tenecteplase'],
    [/tenofovir.*emtricitabine|truvada|TDF\/FTC/i, 'tdf-ftc'],
    [/ticagrelor|brilinta/i, 'ticagrelor'],
    [/unfractionated heparin|^UFH$|heparin sodium/i, 'ufh'],
    [/verapamil|calan|isoptin/i, 'verapamil'],
];
/** Try to find a drug store ID from a drug name string. Returns undefined if no match. */
export function findDrugIdByName(name) {
    for (const [pattern, id] of NAME_TO_ID) {
        if (pattern.test(name))
            return id;
    }
    return undefined;
}
